Research and evaluation
Charity managing England PrEP trial closed down
Chelsea and Westminster NHS Foundation Trust has taken over management of the three-year impact trial, which has now achieved its 10,000 participant target.
The research and education charitable trust managing England’s PrEP impact trial has been wound down by its trustees.
St Stephen’s Clinical Research (SSCR) was part of St Stephen’s AIDS Trust (SSAT), which has been closed after 30 years of research in the field of HIV/AIDS.
Management of the three-year impact trial, which will provide pre-exposure prophylaxis (PrEP) treatment to gather clinical evidence on optimal targeting, uptake and implementation of PrEP on a large scale, was passed to Chelsea and Westminster NHS Foundation Trust on 1 June 2018, but a timeline for transfer of all elements of the trial is still to be confirmed.
Participants in the trial, which launched in September 2017, have been reassured that they should not be affected by the change.
A statement on the trial website said: “If already enrolled on the trial, all participants will be able to continue to access PrEP and attend their follow-up visits”.
NHS England confirmed to The Pharmaceutical Journal that the target number of 10,000 people have now signed up to the trial.
The outcome of the trial, the largest single study of its type in the world, will help inform the potential to roll out PrEP nationwide.
NHS England announced its plans to start the trial of PrEP in December 2016 after it lost an Appeal Court action, which challenged an earlier High Court ruling that NHS England has the power, although not the obligation, to fund PrEP.
Chelsea and Westminster Hospital NHS Foundation Trust said it was “fully committed to continuing SSCR’s and SSAT’s important research and ensuring their legacy will endure into the future”.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20204981
Recommended from Pharmaceutical Press
All you need to know about prescribing or administering drugs via enteral feeding tubes. Over 400 drug monographs as well as facts to inform clinical decision making.£54.00Buy now